Cylex Announces Distribution Partnership with Quest Biomedical (UK)

Cylex Inc. a privately held, venture-capital backed life science Company, announced today it has entered into a distribution arrangement with Quest Biomedical for ImmuKnowTM -- the Cylex® Immune Cell Function Assay and other products into clinical laboratories in the United Kingdom.

Columbia, Maryland (PRWEB) April 5, 2003 --

Cylex Inc. a privately held, venture-capital backed life science Company, announced today it has entered into a distribution arrangement with Quest Biomedical for ImmuKnowTM -- the Cylex® Immune Cell Function Assay and other products into clinical laboratories in the United Kingdom. The assay is used to measure the immune response of patients receiving immunosuppressant therapy for organ transplantation and is the first product cleared by the FDA for measuring global cell-mediated immunity.

Quest Biomedical is a privately held medical diagnostic distributor of products in the transplantation field located in Shirley, Solihull, United Kingdom. The Company currently sells diagnostic products throughout Europe.

Quest BioMedical General Manager, Chris Wall, commented Quest will be launching Cylexs products at the upcoming meeting of the British Society of Transplantation in April, 2003. Our customers tend to be opinion leaders and innovators who are happy to embrace better ways of managing their transplant patients. We welcome, therefore, the opportunity to offer this important new way of monitoring immunosuppressive therapy."

Cylexs President, Judith A. Britz, Ph.D. explained, Quest Biomedical is a uniquely complementary distribution partner because of their existing customer relationships with important transplantation HLA laboratories throughout the United Kingdom. Through Quest Biomedical, Cylexs FDA-cleared assay for the detection of cell-mediated immunity will be offered for the first time outside of the United States addressing a worldwide need for assessment of immunity in immunosuppressed patients."

Cylex is a life science Company that manufacturers and develops patented in vitro diagnostic products for the assessment of immunity. These products have utility for physicians treating life-threatening diseases or conditions who seek to optimize therapy through individualized management of patients immune system, thereby reducing side effects, improving clinical response and quality of life. ImmuKnow is intended to be used as an adjunct to post-transplantation drug level monitoring along with other clinical indicators. Cylexs patented platform technology will also provide an innovative approach for measuring immune activity in AIDS and cancer patients, and those with infectious diseases, autoimmune or other immune system disorders.

Additional information is available on the Companies websites at www.cylex.net and www.questbiomedical.com